{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T14:09:34Z","timestamp":1792418974063,"version":"4.5.0"},"reference-count":32,"publisher":"Wiley","issue":"16","license":[{"start":{"date-parts":[[2018,6,22]],"date-time":"2018-06-22T00:00:00Z","timestamp":1529625600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["acsjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2018,8,15]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Mutations in the colony\u2010stimulating factor 3 receptor (\n                      <jats:italic>CSF3R<\/jats:italic>\n                      ) gene occur frequently in chronic neutrophilic leukemia and are rare in de novo acute leukemia. The objective of this study was to assess the incidence of\n                      <jats:italic>CSF3R<\/jats:italic>\n                      mutations in acute leukemia and their association with other genetic abnormalities.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Amplicon\u2010targeted, next\u2010generation sequencing of 58 genes was performed retrospectively on 1152 patients (acute myeloid leukemia [AML], n\u2009=\u2009587; acute lymphoid leukemia [ALL], n\u2009=\u2009565). Reverse transcriptase\u2010polymerase chain reaction analysis was used to detect 35 leukemia\u2010specific gene fusions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      <jats:italic>CSF3R<\/jats:italic>\n                      mutations (26 patients) were detected in 3.6% (13 of 364 patients), 4.6% (8 of 175 patients), and 8.3% (4 of 48 patients) of those with de novo, relapsed, and secondary AML, respectively, and in 0.2% (1 of 565 patients) of those with ALL. In total, 9 distinct\n                      <jats:italic>CSF3R<\/jats:italic>\n                      mutations were detected. Membrane\u2010proximal missense mutations and cytoplasmic truncations were identified as mutually exclusive. The proportion of patients who had French\u2010American\u2010British subtypes M2 and M4 in the\n                      <jats:italic>CSF3R<\/jats:italic>\n                      \u2010mutated group was significantly greater than that in the\n                      <jats:italic>CSF3R<\/jats:italic>\n                      wild\u2010type group for both the de novo AML cohort (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u2009.001) and the relapsed AML cohort (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u2009.024). All de novo and relapsed AMLs with\n                      <jats:italic>CSF3R<\/jats:italic>\n                      mutations were associated with genetic alterations in transcription factors, including\n                      <jats:italic>RUNX1\u2010RUNX1T1, CBFB\u2010MYH11<\/jats:italic>\n                      , double\u2010mutated CCAAT\/enhancer binding protein \u03b1 (\n                      <jats:italic>CEBPA<\/jats:italic>\n                      dm), and\n                      <jats:italic>NPM1<\/jats:italic>\n                      mutations; and core\u2010binding factor gene abnormalities and\n                      <jats:italic>CEBPA<\/jats:italic>\n                      dm accounted for 90.5% (19 of 21 patients).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      <jats:italic>CSF3R<\/jats:italic>\n                      mutations are uncommon in AML; however, when they occur, they are often associated with core\u2010binding factor gene abnormalities and\n                      <jats:italic>CEBPA<\/jats:italic>\n                      dm. An in\u2010depth understanding of the interaction between these genetic alterations could facilitate a clearer understanding of the role of\n                      <jats:italic>CSF3R<\/jats:italic>\n                      mutations in AML development and may be used for disease classification, prognosis, and the development of targeted therapy.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/cncr.31586","type":"journal-article","created":{"date-parts":[[2018,6,22]],"date-time":"2018-06-22T07:37:36Z","timestamp":1529653056000},"page":"3329-3338","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":60,"title":["<scp>CSF3R<\/scp>\n                    Mutations are frequently associated with abnormalities of\n                    <scp>RUNX1, CBFB, CEBPA,<\/scp>\n                    and\n                    <scp>NPM1<\/scp>\n                    genes in acute myeloid leukemia"],"prefix":"10.1002","volume":"124","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5794-5185","authenticated-orcid":false,"given":"Yang","family":"Zhang","sequence":"first","affiliation":[{"name":"Division of Pathology and Laboratory Medicine, Hebei Yanda Lu Daopei Hospital  Langfang China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Wang","sequence":"additional","affiliation":[{"name":"Division of Pathology and Laboratory Medicine, Hebei Yanda Lu Daopei Hospital  Langfang China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue","family":"Chen","sequence":"additional","affiliation":[{"name":"Division of Pathology and Laboratory Medicine, Hebei Yanda Lu Daopei Hospital  Langfang China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Zhang","sequence":"additional","affiliation":[{"name":"Division of Pathology and Laboratory Medicine, Hebei Yanda Lu Daopei Hospital  Langfang China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingyu","family":"Wang","sequence":"additional","affiliation":[{"name":"Division of Pathology and Laboratory Medicine, Hebei Yanda Lu Daopei Hospital  Langfang China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Liu","sequence":"additional","affiliation":[{"name":"Division of Pathology and Laboratory Medicine, Hebei Yanda Lu Daopei Hospital  Langfang China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panxiang","family":"Cao","sequence":"additional","affiliation":[{"name":"Division of Pathology and Laboratory Medicine, Hebei Yanda Lu Daopei Hospital  Langfang China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoli","family":"Ma","sequence":"additional","affiliation":[{"name":"Division of Pathology and Laboratory Medicine, Hebei Yanda Lu Daopei Hospital  Langfang China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tong","family":"Wang","sequence":"additional","affiliation":[{"name":"Division of Pathology and Laboratory Medicine, Hebei Yanda Lu Daopei Hospital  Langfang China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianping","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Bone Marrow Transplantation, Hebei Yanda Lu Daopei Hospital  Langfang China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xian","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Hematology, Hebei Yanda Lu Daopei Hospital  Langfang China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peihua","family":"Lu","sequence":"additional","affiliation":[{"name":"International Medical Center, Hebei Yanda Lu Daopei Hospital  Langfang China"},{"name":"Beijing Lu Daopei Institute of Hematology  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongxing","family":"Liu","sequence":"additional","affiliation":[{"name":"Division of Pathology and Laboratory Medicine, Hebei Yanda Lu Daopei Hospital  Langfang China"},{"name":"Beijing Lu Daopei Institute of Hematology  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2018,6,22]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-03-643544"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1214514"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2017.32"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/nyas.13097"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-03-705053"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13439"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-04-709899"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-03-209262"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkq603"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.4161\/fly.19695"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V92.2.574"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2017.0116"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-015-0201-1"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-06-509976"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V92.1.32.413k42_32_39"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI3216"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V97.3.829"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-10-695981"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-1054"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-09-687822"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M112.373274"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-015-1764-6"},{"key":"e_1_2_8_24_1","doi-asserted-by":"crossref","unstructured":"FasanA HaferlachC PerglerovaK KernW HaferlachT.CSF3R mutations are predominantly subclonal events in intermediate risk karyotype AML and prevalently occur with CEBPA mutations. Paper presented at: 58th American Society of Hematology (ASH) Annual Meeting; December 3\u20106 2016; San Diego California.","DOI":"10.1182\/blood.V128.22.1658.1658"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-016-2664-4"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2017.163790"},{"key":"e_1_2_8_27_1","volume-title":"Ruxolitinib phosphate in treating patients with chronic neutrophilic leukemia or atypical chronic myeloid leukemia","author":"Oregon Health and Science University (OHSU) Knight Cancer Institute","year":"2017"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2016.376"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2013.773999"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403431"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-08-569228"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0602360103"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-01-329961"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.31586","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.31586","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cncr.31586","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.31586","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T22:20:48Z","timestamp":1761862848000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.31586"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,22]]},"references-count":32,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2018,8,15]]}},"alternative-id":["10.1002\/cncr.31586"],"URL":"https:\/\/doi.org\/10.1002\/cncr.31586","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6,22]]},"assertion":[{"value":"2018-03-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-05-01","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-06-22","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}